CE-C4D method for determination of beta-secretase activity as a tool for unbiased screening of potential drugs for patients suffering from Alzheimer’s disease
Authors | |
---|---|
Year of publication | 2017 |
Type | Conference abstract |
Citation | |
Attached files | |
Description | Alzheimer‘s disease is the most common form of dementia with incidence that almost double every 20 years. It is a progressive disease, where dementia symptoms worsen over a number of years. Although current treatments cannot stop Alzheimer‘s from progressing, they can temporarily slow the worsening of the symptoms. One of the therapeutic targets is the inhibition of beta-secretase enzyme. Inhibition studies are conducted predominantly as a batch-wise screening using probes allowing FRET based determination of the enzyme activity. This approach, however, suffers from fluorescence quenching leading to biased results. As a result, a novel method based on capillary electrophoresis coupled with contactless conductivity detection was developed for separation and quantification of native form of substrate and its hydrolytic products. |
Related projects: |